IL162404A0 - Stabilized formulations of adenovirus - Google Patents
Stabilized formulations of adenovirusInfo
- Publication number
- IL162404A0 IL162404A0 IL16240403A IL16240403A IL162404A0 IL 162404 A0 IL162404 A0 IL 162404A0 IL 16240403 A IL16240403 A IL 16240403A IL 16240403 A IL16240403 A IL 16240403A IL 162404 A0 IL162404 A0 IL 162404A0
- Authority
- IL
- Israel
- Prior art keywords
- adenovirus
- stabilized formulations
- formulations
- stabilized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34922202P | 2002-01-18 | 2002-01-18 | |
PCT/US2003/001055 WO2003061708A1 (en) | 2002-01-18 | 2003-01-15 | Stabilized formulations of adenovirus |
Publications (1)
Publication Number | Publication Date |
---|---|
IL162404A0 true IL162404A0 (en) | 2005-11-20 |
Family
ID=27613260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16240403A IL162404A0 (en) | 2002-01-18 | 2003-01-15 | Stabilized formulations of adenovirus |
Country Status (18)
Country | Link |
---|---|
US (1) | US20030232018A1 (no) |
EP (1) | EP1465664A1 (no) |
JP (1) | JP2005515245A (no) |
KR (1) | KR20040077878A (no) |
CN (1) | CN1617745A (no) |
AR (1) | AR038153A1 (no) |
BR (1) | BR0306925A (no) |
CA (1) | CA2469721A1 (no) |
IL (1) | IL162404A0 (no) |
MX (1) | MXPA04006995A (no) |
NO (1) | NO20043418L (no) |
PE (1) | PE20030851A1 (no) |
PL (1) | PL371261A1 (no) |
RU (1) | RU2004125283A (no) |
TW (1) | TW200307750A (no) |
UY (1) | UY27614A1 (no) |
WO (1) | WO2003061708A1 (no) |
ZA (1) | ZA200406547B (no) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2618838A1 (en) | 2010-09-20 | 2013-07-31 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
US9168292B2 (en) | 2010-09-27 | 2015-10-27 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
KR101875245B1 (ko) | 2010-12-02 | 2018-08-02 | 온콜리틱스 바이오테크 인코포레이티드 | 액체 바이러스 제형 |
JP6034797B2 (ja) | 2010-12-02 | 2016-11-30 | オンコリティクス バイオテク,インコーポレーテッド | 凍結乾燥されたウイルス製剤 |
JP5770952B2 (ja) | 2012-03-12 | 2015-08-26 | クルセル ホランド ベー ヴェー | 改変末端を有する組換えアデノウイルスのバッチ |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
MY169352A (en) | 2012-03-22 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
SI2988780T1 (sl) | 2013-04-25 | 2019-05-31 | Janssen Vaccines & Prevention B.V. | Stabilizirani topni prefuzijski RSV F polipeptidi |
MY171210A (en) | 2013-06-17 | 2019-10-02 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f polypeptides |
JP6735288B2 (ja) | 2015-04-14 | 2020-08-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 双方向性プロモーターを有する2つの導入遺伝子を発現する組換えアデノウイルス |
US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
DK3319633T3 (da) | 2015-07-07 | 2021-02-01 | Janssen Vaccines & Prevention Bv | Vaccine mod rsv |
CA3001050C (en) * | 2015-10-06 | 2023-03-28 | Janssen Vaccines & Prevention B.V. | Method for preventing surface-induced degradation of viruses using cyclodextrins |
KR102491447B1 (ko) | 2016-04-05 | 2023-01-20 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
CA3018941A1 (en) | 2016-04-05 | 2017-10-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f proteins |
CA3023322A1 (en) | 2016-05-12 | 2017-11-16 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
EP3464331B1 (en) | 2016-05-30 | 2020-10-28 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
RU2745500C2 (ru) | 2016-06-20 | 2021-03-25 | Янссен Вэксинс Энд Превеншн Б.В. | Эффективный и сбалансированный двунаправленный промотор |
US10744196B2 (en) | 2016-07-14 | 2020-08-18 | Janssen Vaccines & Prevention B.V. | HPV vaccines |
MX2019009316A (es) | 2017-02-09 | 2019-09-19 | Janssen Vaccines & Prevention Bv | Promotor corto y potente para la expresion de genes heterologos. |
WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
US11229692B2 (en) | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
SG11202001458SA (en) | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
CN116096732A (zh) | 2020-01-31 | 2023-05-09 | 贝斯以色列护理医疗中心有限公司 | 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗 |
JP2024509756A (ja) | 2021-02-19 | 2024-03-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定化された融合前rsv fb抗原 |
WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL179877B1 (pl) * | 1993-07-13 | 2000-11-30 | Rhone Poulenc Rorer Sa | Zdefektowany replikacyjnie adenowirus, linia komórkowa do infekowania zdefektowanym adenowirusem oraz srodek farmaceutyczny PL PL PL PL PL PL PL PL PL PL |
FR2718150B1 (fr) * | 1994-03-29 | 1996-04-26 | Rhone Poulenc Rorer Sa | Virus recombinants, préparation et utilisation en thérapie génique. |
CZ438398A3 (cs) * | 1996-07-01 | 1999-03-17 | Rhone-Poulenc Rorer S. A. | Způsob přípravy rekombinantních adenovirů |
FR2751343B1 (fr) * | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
US6544769B1 (en) * | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
KR100912362B1 (ko) * | 1998-02-17 | 2009-08-19 | 쉐링 코포레이션 | 바이러스 제제의 정제방법 |
US6689600B1 (en) * | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
DE60040727D1 (de) * | 1999-02-05 | 2008-12-18 | Merck & Co Inc | Menschliche papillomavirus impfstoff-formulierungen |
AU4346101A (en) * | 2000-03-07 | 2001-09-17 | Merck & Co., Inc. | Adenovirus formulations |
-
2003
- 2003-01-15 BR BR0306925-7A patent/BR0306925A/pt not_active Application Discontinuation
- 2003-01-15 PL PL03371261A patent/PL371261A1/xx not_active Application Discontinuation
- 2003-01-15 MX MXPA04006995A patent/MXPA04006995A/es unknown
- 2003-01-15 JP JP2003561650A patent/JP2005515245A/ja active Pending
- 2003-01-15 EP EP03731914A patent/EP1465664A1/en not_active Withdrawn
- 2003-01-15 IL IL16240403A patent/IL162404A0/xx unknown
- 2003-01-15 US US10/342,344 patent/US20030232018A1/en not_active Abandoned
- 2003-01-15 KR KR10-2004-7011108A patent/KR20040077878A/ko not_active Application Discontinuation
- 2003-01-15 WO PCT/US2003/001055 patent/WO2003061708A1/en not_active Application Discontinuation
- 2003-01-15 CA CA002469721A patent/CA2469721A1/en not_active Abandoned
- 2003-01-15 RU RU2004125283/15A patent/RU2004125283A/ru not_active Application Discontinuation
- 2003-01-15 AR ARP030100110A patent/AR038153A1/es unknown
- 2003-01-15 CN CNA038023423A patent/CN1617745A/zh active Pending
- 2003-01-17 UY UY27614A patent/UY27614A1/es not_active Application Discontinuation
- 2003-01-17 TW TW092101013A patent/TW200307750A/zh unknown
- 2003-01-17 PE PE2003000051A patent/PE20030851A1/es not_active Application Discontinuation
-
2004
- 2004-08-17 ZA ZA200406547A patent/ZA200406547B/en unknown
- 2004-08-17 NO NO20043418A patent/NO20043418L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PE20030851A1 (es) | 2004-01-01 |
WO2003061708A1 (en) | 2003-07-31 |
EP1465664A1 (en) | 2004-10-13 |
PL371261A1 (en) | 2005-06-13 |
US20030232018A1 (en) | 2003-12-18 |
JP2005515245A (ja) | 2005-05-26 |
BR0306925A (pt) | 2004-11-09 |
RU2004125283A (ru) | 2005-06-10 |
NO20043418L (no) | 2004-08-17 |
AR038153A1 (es) | 2004-12-29 |
CA2469721A1 (en) | 2003-07-31 |
ZA200406547B (en) | 2006-06-24 |
KR20040077878A (ko) | 2004-09-07 |
MXPA04006995A (es) | 2005-07-13 |
UY27614A1 (es) | 2003-08-29 |
TW200307750A (en) | 2003-12-16 |
CN1617745A (zh) | 2005-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL162404A0 (en) | Stabilized formulations of adenovirus | |
IL174420A0 (en) | Stabilized formulations of phosphatidylserine | |
AU2003298738A8 (en) | Liposomal formulations | |
MX294225B (en) | Stabilized compositions comprising probiotics | |
HUP0303732A2 (en) | Hsa-free formulations of interferon-beta | |
IL165349A0 (en) | Microcapsule formulations | |
EP1263461A4 (en) | ADENOVIRUS FORMULATIONS | |
HK1069542A1 (en) | Stabilized oral suspension formulation | |
EP1559433A4 (en) | STABILIZED COMPOSITION | |
AU2003279911A8 (en) | Therapeutic formulations | |
GB0323701D0 (en) | Formulations | |
GB0106601D0 (en) | Antiperspirant formulations | |
IL166591A0 (en) | Preparation of aztreonam | |
GB0202900D0 (en) | Novel formulations of drugs | |
GB0116945D0 (en) | Antiperspirant formulations | |
EP1370240A4 (en) | NEUROPROTECTOR FORMULATIONS AND METHOD | |
GB0116946D0 (en) | Antiperspirant formulations | |
AU2003302372A8 (en) | Formulations of finasteride | |
GB0218194D0 (en) | Solid formulations | |
IL161178A0 (en) | MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES | |
GB0307765D0 (en) | Tissue-adhesive formulations | |
GB0110681D0 (en) | Antiperspirant formulations | |
AU2003298725A8 (en) | Preparation of metallotexaphyrins | |
GB0214147D0 (en) | Formulations | |
GB0115893D0 (en) | Formulations |